Gyncentrum Sp. z o.o.

The dermatology unit at Gyncentrum Sp. z o.o. is investigating immune‑mediated skin disorders, with a focus on Atopic Dermatitis and the potential of novel biologic agents to improve patient outcomes.

• Evaluation of rocatinlimab in combination with topical therapies
• Placebo‑controlled, double‑blind efficacy assessment
• Use of the Validated Investigator’s Global Assessment to measure disease improvement

With 15 investigators contributing, the site aims to expand therapeutic options for immune‑driven skin conditions while maintaining a patient‑focused approach.

Research at this clinic also addresses neuropathic itch, specifically moderate‑to‑severe pruritus linked to Notalgia Paresthetica, by testing oral agents that target nerve‑related pathways.

• Dose‑finding study of difelikefalin versus placebo
• Measurement of itch intensity reduction after eight weeks of treatment
• Assessment of safety and tolerability in adult participants

These trials contribute to a better understanding of how nervous system dysfunction drives chronic itching and explore new avenues for relief.

The department’s broader dermatology program evaluates both disease severity and therapeutic synergy in conditions such as Atopic Dermatitis, integrating systemic and topical approaches.

• Monitoring disease activity with the Eczema Area and Severity Index (EASI)
• Combining topical corticosteroids and calcineurin inhibitors with investigational agents
• Tracking clinical outcomes in moderate‑to‑severe patients

Located in Katowice, Poland, the non‑commercial site leverages its expertise to advance care for skin and connective tissue disorders across Europe.